文献速递认知障碍与痴呆

血浆神经丝轻链与阿尔茨海默病神经退行性变的关联

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2017-01-01

该前瞻性病例对照研究基于阿尔茨海默病神经影像学倡议数据,采用超敏检测法测定193名认知正常对照、197名轻度认知障碍患者和180名阿尔茨海默病痴呆患者的血浆神经丝轻链浓度。结果显示血浆神经丝轻链在轻度认知障碍和阿尔茨海默病痴呆患者中升高,与脑脊液神经丝轻链、认知下降、脑萎缩及脑代谢减低相关,提示其可作为阿尔茨海默病无创生物标志物。

要点

  • 血浆神经丝轻链与脑脊液神经丝轻链显著相关(Spearman ρ=0.59,P<.001)。
  • 轻度认知障碍患者均值42.8 ng/L、阿尔茨海默病痴呆患者均值51.0 ng/L,均高于对照均值34.7 ng/L(P<.001)。
  • 血浆神经丝轻链对阿尔茨海默病痴呆与对照的鉴别AUC为0.87,与现有脑脊液生物标志物相当。

核心结论

  • 血浆神经丝轻链与阿尔茨海默病诊断及认知、生化和影像学标志物相关,提示其作为无创生物标志物的潜在价值。

研究设计与样本

  • 前瞻性病例对照研究,纳入阿尔茨海默病神经影像学倡议中193名认知正常对照、197名轻度认知障碍患者和180名阿尔茨海默病痴呆患者,采用超敏检测法测定血浆神经丝轻链。

主要发现

  • 血浆神经丝轻链与脑脊液神经丝轻链相关(Spearman ρ=0.59,P<.001)。
  • 轻度认知障碍患者血浆神经丝轻链均值42.8 ng/L、阿尔茨海默病痴呆患者均值51.0 ng/L,均高于对照均值34.7 ng/L(P<.001)。
  • 血浆神经丝轻链对阿尔茨海默病痴呆与对照的鉴别AUC为0.87。
  • 伴有Aβ病理特征的轻度认知障碍和阿尔茨海默病痴呆患者血浆神经丝轻链尤其高。
  • 高血浆神经丝轻链与认知功能差、阿尔茨海默病相关脑萎缩(基线和纵向)及脑代谢减低(纵向)相关。

临床怎么用

  • 血浆神经丝轻链可作为阿尔茨海默病神经退行性变的非侵入性血液生物标志物,用于辅助诊断和疾病进展评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. OBJECTIVE: To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS: In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. The study dates were September 7, 2005, to February 13, 2012. The plasma NFL analysis was performed in September 2016. MAIN OUTCOMES AND MEASURES: Associations were tested between plasma NFL and diagnosis, Aβ pathologic features, CSF biomarkers of neuronal injury, cognition, brain structure, and metabolism. RESULTS: Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman ρ = 0.59, P < .001). Plasma NFL was increased in patients with MCI (mean, 42.8 ng/L) and patients with AD dementia (mean, 51.0 ng/L) compared with controls (mean, 34.7 ng/L) (P < .001) and had high diagnostic accuracy for patients with AD with dementia vs controls (area under the receiver operating characteristic curve, 0.87, which is comparable to established CSF biomarkers). Plasma NFL was particularly high in patients with MCI and patients with AD dementia with Aβ pathologic features. High plasma NFL correlated with poor cognition and AD-related atrophy (at baseline and longitudinally) and with brain hypometabolism (longitudinally). CONCLUSIONS AND RELEVANCE: Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. This finding implies a potential usefulness for plasma NFL as a noninvasive biomarker in AD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Mattsson N, Andreasson U, Zetterberg H, et al. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017. PMID: 28346578. doi:10.1001/jamaneurol.2016.6117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。